Vaxinano
Vaxinano is a clinical stage biotech company dedicated to developing innovative nasal and thermostable vaccines for human and animal health. Founded in 2016, the company leverages nanomedicine and proprietary vaccine platforms to address unmet needs in infectious diseases, with a focus on mucosal immunotherapy and vaccine delivery systems. Vaxinano collaborates globally, supports wildlife conservation through its WildVax program, and has received recognition for its impactful contributions to vaccine technology.
Industries
Products
Nasal toxoplasmosis vaccine candidate (antigen-loaded lipidated nanoparticles)
Inactivated-antigen or protein vaccine candidate formulated in maltodextrin-based lipid-core nanoparticles for intranasal administration to induce Th1/Th17 cellular immunity and prevent/reactivate Toxoplasma gondii infection.
Canine leishmaniasis vaccine candidate (nasal immunotherapy)
Nasally administered immunotherapeutic vaccine formulation evaluated in naturally infected dogs to strengthen deficient immune responses against Leishmania infantum.
Nasal toxoplasmosis vaccine candidate (antigen-loaded lipidated nanoparticles)
Inactivated-antigen or protein vaccine candidate formulated in maltodextrin-based lipid-core nanoparticles for intranasal administration to induce Th1/Th17 cellular immunity and prevent/reactivate Toxoplasma gondii infection.
Canine leishmaniasis vaccine candidate (nasal immunotherapy)
Nasally administered immunotherapeutic vaccine formulation evaluated in naturally infected dogs to strengthen deficient immune responses against Leishmania infantum.
Services
Wildlife and zoo vaccination programs (conservation field deployment)
Coordination and delivery of intranasal vaccination campaigns for endangered and captive species in partnership with zoological institutions.
Licensing and partnership collaborations for veterinary vaccine development
Commercial licensing and collaborative R&D agreements with animal-health companies including transfer of vaccine candidates and co-development funding.
Wildlife and zoo vaccination programs (conservation field deployment)
Coordination and delivery of intranasal vaccination campaigns for endangered and captive species in partnership with zoological institutions.
Licensing and partnership collaborations for veterinary vaccine development
Commercial licensing and collaborative R&D agreements with animal-health companies including transfer of vaccine candidates and co-development funding.
Expertise Areas
- Mucosal vaccine development
- Nanoparticle vaccine formulation
- Thermostable vaccine formulation and distribution
- Preclinical animal models for infectious diseases
Key Technologies
- Mucosal (intranasal) vaccine delivery
- Double-core nanoparticle platforms
- Maltodextrin-based lipid-core nanoparticles
- Thermostable vaccine formulations